We report two cases of multidrug-resistant
endometrial cancer which recurred after the initial
therapy and progressed despite further anticancer
chemotherapy, but could be successfully treated with
medroxyprogesterone acetate (MPA). The first patient with stage IVb moderately-differentiated
endometrioid adenocarcinoma of the uterine corpus underwent initial operation and postoperative
chemotherapy followed by
maintenance chemotherapy. Four months later, lung
metastases were found. Since the
hormone receptor status was positive, the patient was treated with MPA, and CR was achieved. The second patient with stage IIIc poorly-differentiated
endometrioid adenocarcinoma of the uterine corpus developed lung
metastases 14 months after the initial operation and postoperative
chemotherapy. Subsequent
chemotherapy yielded a complete response(CR). Two months later, however, a small intestinal
metastasis was observed, which was treated by surgical excision and
chemotherapy. The patient again remained disease-free for four months until lung
metastases were observed. Since the
hormone receptor status was positive, the patient was treated with MPA, and CR was achieved. No serious adverse events were observed in either patient.